An independent data and protection monitoring board examined the trial data and made recommendations relating to the continuation of the analysis. The first author ready the 1st draft of the manuscript, with the help of a medical writer who was simply funded by Novartis Pharmaceuticals, and made the final decision to post the manuscript for publication. All the authors and representatives of the sponsor reviewed and amended the manuscript. All the authors vouch for the precision and completeness of the data and verify that the study as reported conforms to the protocol and statistical analysis strategy .Naloxone is used by trained medical employees and first responders commonly. Its use among non-medical personnel, such as family friends or users who witness an overdose, has recently increased within an effort to reduce opioid overdose deaths. At the FDA meeting, Dr. Gupta, who also serves as a special government employee of the FDA Analgesic and Anesthetic Drug Products Advisory Committee, expressed ASA’s support for expanding access to naloxone to more non-medical staff. Dr. Gupta explained that the federal government and stakeholders should increase the option of naloxone to people likely to witness an opioid overdose and train them on how to recognize an opioid overdose, and on effective resuscitation and post-resuscitation care.